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Structure of human immunoproteasome with a
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selectively inhibits activated lymphocytes
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Proteasome inhibitors beneﬁt patients with multiple myeloma and B cell-dependent auto-
immune disorders but exert toxicity from inhibition of proteasomes in other cells. Toxicity
should be minimized by reversible inhibition of the immunoproteasome β5i subunit while
sparing the constitutive β5c subunit. Here we report β5i-selective inhibition by asparagine-
ethylenediamine (AsnEDA)-based compounds and present the high-resolution cryo-EM
structural analysis of the human immunoproteasome. Despite inhibiting noncompetitively, an
AsnEDA inhibitor binds the active site. Hydrophobic interactions are accompanied by
hydrogen bonding with β5i and β6 subunits. The inhibitors are far more cytotoxic for mye-
loma and lymphoma cell lines than for hepatocarcinoma or non-activated lymphocytes. They
block human B-cell proliferation and promote apoptotic cell death selectively in antibody-
secreting B cells, and to a lesser extent in activated human T cells. Reversible, β5i-selective
inhibitors may be useful for treatment of diseases involving activated or neoplastic B cells or
activated T cells.
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Degradation of most cytosolic proteins is a highly regulated,ATP-dependent cellular activity executed by theubiquitin-proteasome system (UPS)1. The UPS plays
essential roles in diverse cellular activities, including cell cycle
control, signal transduction, protein homeostasis and immune
surveillance. The degradation machinery of the UPS, the 26 s
proteasome, is composed of a hydrolytic barrel-like 20 s core and
regulators, such as 19 s or 11 s, on either or both ends of the 20 s.
The 20 s core that is constitutively expressed in most cells (c-20S)
is a stack of 4 rings of 14 α and 14 β subunits organized in a
α1–7β1–7β1–7α1–7 fashion, where 2 copies of each caspase-like β1,
trypsin-like β2 and chymotrypsin-like β5 active subunit are
located in the inner β rings2. The chymotrypsin-like β5 active
subunit of the 20 s has been clinically validated as a target for the
treatment of multiple myeloma and certain lymphomas. The
Food and Drug Administration-approved drugs bortezomib and
carﬁlzomib represent two classes of covalent proteasome inhibi-
tors: reversible peptide boronates and irreversible peptide epox-
yketones, respectively3. Several other classes of proteasome
inhibitors have been identiﬁed and optimized, such as β-lactones
and peptide sulfonyl ﬂuorides4. However, their reactive warheads
pose a challenge for developing a drug candidate. Several non-
competitive proteasome inhibitors have recently been
reported5–7.
We have been developing isoform-selective, non-covalent
inhibitors for various proteasomes, such as the Mycobacterium
tuberculosis proteasome8–12 and the human immunoproteasome
(i-20 s)13–15. I-20S is expressed in cells of the immune system and
other cells exposed to cytokines that are elevated during immune
responses, where the active subunits β1c, β2c, and β5c in c-20S
are replaced by β1i, β2i and β5i, respectively16–18. The i-20S
serves diverse functions in the immune system, including the
provision of oligopeptides for antigen presentation, T cell dif-
ferentiation and proliferation19,20. Antibody-secreting plasma
cells are highly sensitive to proteasome inhibition. Bortezomib,
which inhibits both c-20s and i-20S, has been used in renal
transplant recipients to treat antibody-mediated graft rejection21.
Bortezomib was also reported to be efﬁcacious in patients with
refractory systemic lupus erythematosus22. However, bortezo-
mib’s substantial mechanism-based toxicity requires use of much
reduced doses in the treatment of non-malignant conditions.
To regulate immune responses through proteasome inhibition
with less mechanism-based toxicity to immune cells and little or
none to other cells, it would be useful to inhibit i-20S selectively,
sparing c-20S. Consistent with this notion, and unlike disruption
of genes encoding c-20S subunits, disruption of genes encoding
β1i, β2i and β5i results in mice that are healthy, fertile and
immunocompetent23. Indeed, relatively selective inhibition of β5i
over β5c with the compound ONX-0914 has been efﬁcacious in
several mouse models of autoimmune disease24. However, ONX-
0914 belongs to the peptide epoxyketone class of inhibitors whose
irreversible mechanism involves recruiting the hydroxyl and
amino groups of the active site Thr1N into formation of a 1,4-
oxazepane adduct with the epoxyketone warhead. Long-term use
of an irreversible inhibitor presents a risk of toxicity from the
gradual, cumulative inhibition of c-20S and potentially of other
targets. Therefore, it would be desirable to develop inhibitors that
are highly selective for i-20S as well as reversible25. Several recent
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Fig. 1 AsnEDAs noncompetitively inhibit β5i and β5c. a Dipeptide DPLG3 and AsnEDA PKS21004 and PKS21003. b PKS21004 potently and dose-
dependently inhibits β5i and β5c, whilst PKS21003 is inactive. c PKS21004 reversibly inhibits β5c. d–g kinetics studies of modality of inhibition for
PKS21004 against β5i (d, e) and β5c (f, g). d Steady state velocities in the presence of PKS21004 at the concentrations indicated next to each curve. Data
as in d are shown in double reciprocal plots in e, and data from f in g. Values of Ki and α for PKS21004 were determined to be 0.077 µM and 0.28 µM for
β5i, and 0.55 µM and 0.65 for β5c, respectively, by ﬁtting the data to an equation for noncompetitive inhibitors. Data are means± SEM of three
independent experiments
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studies have reported the development of β5i-selective inhibi-
tors26,27. Because of the abundance of proteasomes’ substrates, an
additional beneﬁt might accrue from a noncompetitive mode of
action, so that progressive accumulation of substrate does not
lessen the degree of inhibition. Herein we report the serendipitous
discovery of a class of non-covalent compounds that non-
competitively and selectively inhibit β5i over β5c.
Results
Scaffold morphing from dipeptides to AsnEDAs. We recently
reported a class of irreversible inhibitors that selectively inhibit
the Mycobacterium tuberculosis proteasome over human c-20S11.
We later found that this class of inhibitors also selectively inhibits
i-20S over c-20S13, reﬂecting that the mycobacterial and human
i-20S proteasomes share similar folding around the β5i active
subunit. We later identiﬁed non-covalent N,C-capped dipeptides
with bulky hydrophobic aromatic rings at P1 and N,N- dual
substituted asparagine side chains that are highly potent and
selective for Mtb20S over both human c-20S and i-20S12,28. We
then developed a class of N,C-capped dipeptidomimetics by
incorporating a β-amino acid into the N,C-capped dipeptides,
which resulted in markedly potent and selective inhibitors for β5i
over β5c15. We also developed β5i-selective N,C-capped dipep-
tides that suppressed T-cell activation and proliferation in vitro
and helped prevent rejection of cardiac allografts in mice14.
To move away from peptides, we systematically replaced the
amide bonds in select N,C-capped dipeptides with bioisosteres.
Reversing the amide bond at the C-cap and replacing the amino
acid with an aromatic carboxylic acid resulted in a chemotype:
Asn-ethylenediamine (AsnEDA) (Fig. 1a). The ﬁrst compound of
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Fig. 2 Structure of the human i-20S bound to PKS21004, determined by high-resolution cryo-EM and single-particle analysis. a Surface view of the cryo-
EM map with each subunit colored differently. b Electron densities of four selected α-helices demonstrating the resolution of many side chains of the i-20S
complex. c A vertical central section of the 3.8-Å cryo-EM density map rendered as surface view. The inhibitor density is highlighted in green. d The
electron density of the PKS21004 in the β5i active site shown as blue meshes with modeled atomic structure shown as green sticks. The structure of the
β5i is shown as cartoon in magenta and β6 in salmon, respectively. The proteolytic residue Thr1 of β5i is in red sticks. e A stereo view of the binding pose of
PKS21004
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this class, PKS3080, yielded modest IC50s of 0.37 and 1.22 µM
against human β5i and β5c, respectively. Replacement of the 1-
naphthoyl with 2-naphthoyl (producing PKS21025) improved
potency against β5i by 3-fold and increased selectivity to 26-fold.
Replacement of the N-cap 1-naphthoyl with [1,1′-biphenyl]-4-
carboxamide (PKS21003) and [1,1′-biphenyl]-3-carboxamide
(PKS21004) drastically impacted activity. PKS21003 had no
detectable activity against either β5i or β5c (IC50> 100 µM for
both), whereas PKS21004 was a potent inhibitor of both β5i and
β5c, with IC50s of 0.058 and 0.326 µM, respectively (Fig. 1b).
Inhibition of the β5 subunits was speciﬁc, as no inhibition was
observed of β1 or β2 activities in either i-20S or c-20S
(Supplementary Table 1).
Modality of inhibition. As expected from their non-covalent
chemistry, dialysis of a pre-incubated mixture of c-20S and
PKS21004 fully restored β5c activity (Fig. 1c), conﬁrming the
reversibility of this class of inhibitors. Kinetic analysis indicated
that PKS21004 inhibits β5i and β5c noncompetitively with sub-
strate. With increasing concentrations of PKS21004, both Vmax
and KM decreased (Fig. 1d–g and Supplementary Fig. 1). This
indicates that inhibition of β5i and β5c by PKS21004 is of a mixed
noncompetitive type with αc-20S≈ 0.65 and αi-20S≈ 0.2829, and
that PKS21004 binds more tightly to both β5c and β5i with
substrate bound than without substrate (Supplementary Fig. 1).
Decreasing Vmax/KM with increasing PKS21004 concentration
also suggests that PKS21004 is not an uncompetitive inhibitor of
either 20S (Supplementary Fig. 1)29. This class thus joins a
growing list of noncompetitive proteasome inhibitors5,30.
Cryo-EM structure of human i-20S with PKS21004. To identify
the binding site of the compound, we used high-resolution cryo-
electron microscopy and single-particle analysis to determine the
structure of the human immunoproteasome in complex with
PKS21004 (See Experimental methods). The ﬁnal cryo-EM 3D
map had a resolution of 3.8 Å in which the secondary structures
such as β-strands and α-helices were very well resolved (Fig. 2a,
Supplementary Figs. 2–6). Many large side chains were also
resolved (Fig. 2b). The large side chain densities, in conjunction
with the previously published crystal structures of the human
constitutive proteasome (PDB code 5LF1)25 and the mouse
immunoproteasome (PDB code 3UNH)31, enabled us to build an
atomic model at this resolution (see Table 1 for model statistics).
In the electron density map and the atomic model, the very long
carboxyl terminal extension of the human β2i embraces nearly
half of the β3 subunit (Fig. 2a); this feature is highly conserved
from yeast to humans (Supplementary Fig. 7).
We were able to unambiguously assign the density in the
substrate-binding cleft near the active site of β5i to PKS21004
(Fig. 2c–e). No additional densities were observed in the active
site of any other β-subunits or in any of the α− subunits. This
result is consistent with the conclusion that PKS21004 speciﬁcally
inhibits the activity of the β5 subunits. PKS21004 binds to human
i-20S between β5i and β6 at a position similar to where the
covalent inhibitor dihydroeponemycin binds in the β1c, β2c, and
β5c of the human c-20S (PDB code 5LF1)25.
PKS21004 is largely hydrophobic and interacted with β5i and
β6 primarily via hydrophobic contacts (Fig. 3a–b, Supplementary
Fig. 8A, B). Speciﬁcally, the R1 group extended deeply into the S1
and S1 sub pocket (S1SP), forming extensive hydrophobic
contacts with Ala20, Val31, Ser46, Gly47, Ala49, and Gln53 of
β5i, and Tyr130 of β6; the R2 group, being outside of the active
site, interacted with Ser21, Ala22, and Cys48 of β5i, and Val127 of
β6; the R3 group was next to the β6 subunit, forming interactions
with Ala28 of β5i, and Ser123, Phe124, Ser129, and Gln131 of β6.
The inhibitor also formed two hydrogen bonds, one between the
R3 group and Ser27 of β5i, and the other between R3 and Asp125
of β6. The overall structures of the catalytic β1i, β2i, and β5i are
very similar to their constitutive counterparts, except for several
minor differences in the loop regions (Supplementary Fig. 9A).
However, among the human β5i residues interacting with
PKS21004, many are different from their corresponding residues
in the human β5c (Supplementary Figs. 8, 9B). Notably, Ala27
and Ser53 in β5c are replaced by Ser27 and Gln53 in β5i, thus
disrupting two important interactions with PKS21004 in the β5i
(Fig. 3c, Supplementary Fig. 8A, C). The side chain of Met45 is
swung outward as compared to the apo human β5c or β5c in
complex with CFZ to accommodate the bulky R1 group in β5i.
(Supplementary Fig. 10). These differences may explain why
PKS21004 selectively inhibits i-20S over c-20S.
The seeming discrepancy between kinetic and structural
studies indicates that PKS21004 belongs to a class of active site-
directed noncompetitive inhibitors, along with certain inhibitors
of other enzymes, especially kinases32. However, to our knowl-
edge, this is the example of an active site-directed noncompetitive
inhibitor of proteasomes.
Optimization of AsnEDAs. The foregoing features of these
AsnEDA compounds encouraged a further round of SAR studies
(Table 2) in which we varied the carboxylic acid at the ethyle-
nediamine, the N-cap at the Asn, and the side chain of Asn, of
PKS21004. All compounds listed in Table 1 were synthesized as
illustrated in Scheme 1–9 in Supplementary Methods. The
structures of all ﬁnal compounds were conﬁrmed by nuclear
magnetic resonance (NMR) and high-resolution mass spectro-
scopy (HRMS). IC50s of all compounds against β5i and β5c
(Table 2) and against β1i, β2i, β1c, and β2c (Supplementary
Table 1) were determined following reported methods8. All
compounds were speciﬁc for the β5 subunit; no inhibition of β1i,
β1c, β2i, or β2c was observed. Comparison of the
Table 1 Cryo-EM data collection and reﬁnement statistics
Human i-20S-PKS21004 (EMD-7010, PDB 6AVO)
Data collection
EM equipment JEOL JEM-3200FS
Voltage (kV) 300
Detector Gatan K2 Summit
Pixel Size (Å) 1.2
Electron Dose (e− Å−2) 60
Underfocus range (µm) 1.0–3.0
Reconstruction
Software RELION 2.0
Number of particles used 75,017
Resolution (Å) 3.8
Map-sharpening B factor (Å2) 124.3
Model composition
Peptide chains 28
Protein residues 6115
Ligands 2
R.m.s deviation
Bond length 0.009
Bond angle 1.146
Ramachandran plot
Preferred (%) 90.70
Allowed (%) 9.22
Outlier (%) 0.08
Validation
MolProbity score 2.52
Good rotamer (%) 98.02
Clashscore, all atoms 32.47
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ethylenediamine with a methyl-ethylenediamine (PKS21018) and
a 1,3-propyldiamine (PKS21019) indicated that the ethylenedia-
mine gave the greatest potency for β5i and selectivity over β5 c.
We then modiﬁed the [1,1′-biphenyl]-3-carboxamide of
PKS21004 with the following substituents: 4′-F (PKS21026), 4′-
cyano (PKS21028), 4-F (PKS21196), 4,3′-diF (PKS21195) and
4,2′-diF (PKS21187). The 4′-substitutions decreased potency,
while 4- and 4,3′- substitutions did not. Best, 4,2′-diF-
(PKS21187) improved potency against β5i to IC50 0.015 µM and
improved selectivity to ~20-fold over inhibition of β5c. Consistent
with these results, the binding pocket in the cryo-EM structure is
large enough to accommodate the new ﬂuoride in 4- and 4,3′-
positions. Notably, two crucial residues around these sites, Ser46
and Gln53 in β5i, are changed to Ala46 and Ser53 in β5c, which
may account for the improved potency of PKS21187 against β5i
over β5c (Supplementary Fig. 8A–D).
Next, we investigated a N-Boc-Asp-tBu substitution on
PKS21277, an intermediate in the synthesis of PKS21187.
Compared with PKS21187, PKS21277 has a smaller R2 group,
which may abolish the interactions with Val127 in β6 and Cys48
in β5i that is changed to Gly48 in β5c (Supplementary Fig. 8A–C).
Consistently, PKS21277 was modestly potent against β5i, with 36-
fold selectivity over β5c (Table 2, Supplementary Fig. 8D).
Replacing the Asp-tBu with Gly (PKS21276), Ala (PKS21280), or
Asn (PKS21281) abolished the inhibitory activities against both
β5i and β5c, suggesting that Asp-tBu is critical for optimal
binding to β5 (Supplementary Fig. 8). We then replaced
phenylpropionate with tosyl on the N-cap of the Asn of
PKS21187, yielding PKS21221. Based on the cryo-EM structure,
the tosyl group may form tighter interactions with Ser27 and
Cys48 in the human β5i (Supplementary Fig. 8). IC50s were
determined to be 4 nM against β5i and 110 nM against β5c,
representing 30-fold selectivity. Again, replacing the Asp-tBu of
PKS21221 with Gly (PKS21289), Ala (PKS21290), or Asn
(PKS21288) eliminated inhibitory activity against both β5i and
β5c. We then replaced the tosyl of PKS21221 with acetyl which
yielded PKS21294. PKS21294 showed much reduced potency in
comparing to PKS21221 by 150-fold against β5i, by 120-fold
against β5c. Replacing the tosyl of PKS21221 with cyclopropa-
nesulfonyl, yielded PKS21293 that showed 3.7-fold reduction in
potency against β5i in comparing to PKS21221. However, its
selectivity against β5i over β5c was improved from 27.5-fold to
64-fold.
To corroborate that the noncompetitive modality of inhibition
was shared among this class of compounds, we tested PKS21221
against β5i and conﬁrmed the noncompetitive mechanism; α was
β5i subunit
Ala20Ser21
Thr1
Ala22
Ser27
Val31
Ser46Gly47Cys48
Ala49 Gln53
Ala28
β6 subunit
Gln131Ser123
Phe124
Asp125
Val127
Ser129
Ser27
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c
a b
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Fig. 3 The interaction of PKS21004 with the human i-20S. a Detailed hydrophobic interactions between the R1 and R3 groups of PKS21004 with the
substrate pocket of the human β5i subunit. A hydrogen bond between Ser27 and the oxygen atom of the PKS21004 R3 group (3.0 Å) is shown as a dashed
red line. b Interactions of the R2 and R3 groups of PKS21004 with the neighboring β6 subunit. The strong H-bond between Asp125 and the nitrogen atom
of the R2 of PKS21004 (2.66 Å) is shown by a dashed red line. c Representation of the PKS21004 (green sticks) in the β5i active site (purple cartoon). The
structure of β5 (gray cartoon, PDB 5LF1) is superimposed for comparison. The right panel is an enlarged and rotated view of the area in the square box of
the left panel. Red dots denote the active residue Thr1 of β5 and β5i. The two residues in human β5i that make contact with the inhibitor and are different
from the human β5c are shown in stick and marked by two black arrows
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determined to be 0.26 (Supplementary Fig. 11), in agreement with
that of PKS21004.
PKS21221 selectively induces cell death in MM cells. To
determine if this class of inhibitors is cell penetrable, we treated
the B-cell lymphoma line Karpas 1106P28 (expressing a high
proportion of i-20S over c-20S) with PKS21221 before incubation
with either (Ac-ANW)2-R110 (a speciﬁc substrate of β5i) or suc-
LLVY-luciferin (a substrate of β5) (Fig. 4a). IC50 values with both
substrates were almost identical (172 and 118 nM) and indicated
the cell-penetrating ability of these compounds. Similarly,
PKS21221 inhibited β5c activity in HepG2 hepatoma cells with an
IC50 of 1833 nM (Table 3). No β5i activity was detected in
HepG2 cells using (Ac-ANW)2-R110 as a substrate. PKS21221
itself does not inhibit luciferase activity at 100 µM when tested
over the range 0.002–100 µM.
Multiple myeloma cells are hypersensitive to inhibition of
chymotryptic activity of their proteasomes and the pan-
proteasome inhibitor bortezomib has clinical beneﬁt in patients
with multiple myeloma33,34. We incubated MM.1S, RPMI 8226,
Karpas and HepG2 cells with PKS21221 at different concentra-
tions, and determined cell viability after 72 h (Fig. 4b).
PKS21221 showed potent cytotoxicity against the myeloma cell
lines MM.1S and RPMI 8226, but was ~10-fold and ~30-fold less
Table 2 SAR studies and IC50s of compounds against human β5i and β5c
ID
IC50 (μM)
R2 R3 R1
H
CH3
H
CH3
H
CH3CO–
PKS3080
PKS21025
PKS21003
PKS21004
PKS21018
PKS21019
PKS21026
PKS21028
PKS21196
PKS21195
PKS21187
PKS21277
PKS21276
PKS21280
PKS21281
PKS21284
PKS21221
PKS21289
PKS21290
PKS21288
PKS21294
PKS21293
β5i
0.37
0.091
>100
0.058
2.35
0.28
0.11
2.07
0.044
0.059
0.016
0.11
24.25
33.23
>100
1.0
0.004
40.3
> 100
4.14
0.62
0.015
β5c
1.22
2.607
>100
0.326
13.93
3.05
1.16
7.25
0.68
1.94
0.36
3.80
>100
>100
>100
3.84
0.11
60.8
> 100
> 100
13.26
0.96
All IC50s are means of at least three independent experiments, except that IC50s greater than 10 µM are means of two independent experiments
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cytotoxic against the Karpas lymphoma cell line and the HepG2
hepatocarcinoma cell line cells, respectively (Table 3).
PKS21221 is selectively cytotoxic to ASC’s. The immunopro-
teasome plays important roles in T cell differentiation and pro-
liferation and dendritic cell activation and maturation14,20,24.
However, its role in B cell differentiation is not well understood.
The pan-proteasome inhibitor bortezomib depleted plasma cells
in mice with lupus-like disease35. To investigate whether an
immunoproteasome-selective inhibitor impacts the survival of B
cells, especially differentiated antibody-secreting cells (ASCs), we
differentiated B cells in human peripheral blood mononuclear
cells (PBMCs) into CD19+CD38+CD27+ ASCs in the presence of
IL-2 and toll-like receptor (TLR)7/8 agonist R848 for 5 days36,37.
Differentiated ASCs were then exposed to PKS21221 at indicated
concentrations and cell survival was determined with Annexin V
and 7-aminoactinomycin D (7-AAD) at three-time points
(12-h, 24-h, and 48-h after treatment). The percentage of viable
ASC decreased with PKS21221 treatment in a dose- and
time-dependent manner (Fig. 5a, Supplementary Fig. 12b, c),
while the overall viability of PBMCs was not affected (Fig. 5b,
Supplementary Fig. 12D). This was explained by enhanced
apoptosis (Fig. 5c, d, left) and cell death (Fig. 5c, d, right) of the
ASCs. Apoptosis of CD19+ non-ASCs was slightly enhanced but
no increase was observed in apoptosis of CD19− cells (Fig. 5e,
left). Similarly, PKS21221 treatment did not affect viability of
CD19− cells or CD19+ non-ASCs (Fig. 5e, right). These results
suggest that PKS21221 speciﬁcally affected the viability of ASCs
and to a lesser extent, non-antibody-secreting CD19+ B cells. In
addition, the cytotoxicity of PKS21221 to different cell
populations in PBMC was examined and compared to the
cytotoxicity of bortezomib. PBMCs were incubated with
PKS21221 or bortezomib, and the viability was assessed in
T cells (CD3+), B cells (CD19+), monocytes (CD14+) and den-
dritic cells (CD3−CD19−CD14−CD16−CD11c+HLA-DR+),
respectively (Supplementary Fig. 13b–e). We compared 10 nM
bortezomib to 1 μM PKS21221 as these concentrations gave
comparable reductions in ASCs in the differentiation culture
(Supplementary Fig. 12B). Bortezomib was more cytotoxic at
10 nM than PKS2122 at 1 µM to resting CD3+ T cells and CD19+
B cells in (Supplementary Fig. 13b, c), suggesting that PKS21221
was more selectively cytotoxic than bortezomib for activated
B cells and ASCs.
PKS21221 inhibits proliferation of T cells. As we observed
selective cytotoxicity of PKS21221 in activated B cells and ASCs
compared to non-activated B cells, we asked whether this is the
case in proliferating T cells. We activated human T cells to
proliferate with anti-CD3 and anti-CD28 in the presence or
absence of PKS21221 or bortezomib. Both compounds inhibited
proliferation of T cells in a dose-dependent manner (Fig. 6a, b).
To examine whether these inhibitors are cytotoxic preferentially
to proliferating cells, we triggered T-cell proliferation with anti-
CD3/anti-CD28 for 4 days (in the absence of inhibitors), treated
the cells with PKS21221 for the next 24 h and determined cell
survival with Annexin V and 7-AAD (Fig. 6c, d). Both PK21221
and bortezomib induced apoptosis and cell death to a greater
extent in proliferating T cells than in non-proliferating T cells,
suggesting that proteasome inhibitors preferentially affect survival
of activated, proliferating T cells.
Discussion
These results introduce a versatile new scaffold of proteasome
inhibitors, describe their potential for optimization for selective
inhibition of the immunoproteasome over the constitutive pro-
teasome, present the cryo-EM structure of the human immuno-
proteasome in complex with an inhibitor, and demonstrate the
inhibitors’ ability to kill myeloma cells, activated human B cells
and ASCs in vitro, and to a lesser extent, proliferating human
T cells.
To our knowledge, the structure of the human immunopro-
teasome has not been previously reported, nor has a structure
previously been reported of any immunoproteasome with a
kinetically noncompetitive inhibitor. The enhanced interior
resolution allowed us to conﬁdently interpret the favorable
binding of PKS21004 in β5i over β5c and is guiding structure-
activity relationship studies to improve potency and selectivity.
How active site-binding AsnEDAs kinetically behave like non-
competitive inhibitors remains to be determined. Active site-
directed noncompetitive inhibitors of other enzymes have been
reported and mechanistic investigations have suggested several
possibilities32. A molecular dynamics study of the proteasome
suggested that conformational changes are induced upon binding
of an inhibitor to one β5 that are propagated to the trans-β5 in
the other β ring through β438. That mechanism does not appear
to apply here, as the Hill coefﬁcient constant is ~1 for the inhi-
bition of either β5i or β5c by either PKS21004 or PKS21221,
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Fig. 4 Intracellular proteasome inhibition by PKS21221 and its cytotoxicity against transformed cell lines. a Karpas 1106P lymphoma cells (white and black
symbols) or HepG2 cells (blue symbols) were treated with PKS21221 for 2 h at the concentrations indicated prior to incubation with substrate (Ac-
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listed in the Table 3. Data are means± SEM of three to four independent experiments
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01760-5 ARTICLE
NATURE COMMUNICATIONS |8:  1692 |DOI: 10.1038/s41467-017-01760-5 |www.nature.com/naturecommunications 7
respectively. It remains to be investigated if binding of inhibitor
to one β5 only affects the hydrolytic activity of the trans-β5, but
not its binding of substrate.
A growing body of evidence shows that selective inhibition of
the immunoproteasome is beneﬁcial in immunity-related diseases
without the mechanism-based toxicity of indiscriminate inhibi-
tion of all proteasomes. Some immune cells are highly susceptible
to proteasome inhibition. For example, plasmacytoid dendritic
cells39 and plasma cells40 are hypersensitive to bortezomib.
However, differential hypersensitivity of immune cells towards
selective β5i inhibition is unknown. Here we show that malignant
myeloma cells are susceptible to β5i inhibition. Furthermore, we
found that differentiated ASCs and proliferating T cells are sus-
ceptible to β5i inhibition. This suggests the potential clinical
utility of β5i-selective inhibitors in the treatment of diseases with
dysregulated B-cell activity, such as antibody-mediated allograft
rejection or autoantibody-exacerbated disorders such as lupus
and type 1 diabetes. Such effects may be enhanced by inhibition
of the proliferation of helper T cells.
To our knowledge, this is a reported example of active site-
directed noncompetitive proteasome inhibitors. Unlike competi-
tive inhibitors whose intracellular activity is expected to diminish
if substrates accumulate, noncompetitive inhibitors are expected
to retain a similar degree of inhibitory activity with substrate
accumulation, or even increased activity, given that the binding of
AsnEDA compounds to β5c and β5i was enhanced by substrate.
Methods
Reagents. The human 20S immunoproteasome core sample was purchased from
Boston Biochem. The human i-20s at a concentration of 1.5 mg per ml was
incubated with PKS21004 dissolved in DMF with a molar ratio of 1:250 ratio for
1 h at 37 °C, then the mixture was diluted in 50 mM HEPES, pH 7.6, 100 mM NaCl
and 1 mM dithiotreitol to a ﬁnal concentration of 0.1 mg per mL for cryo-EM
study. Antibodies used for ﬂow cytometry are described as below (clone, company):
CD3 (UCHT1, Biolegend), CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), CD11c
(3.9, Biolegend), CD14 (RMO52, Beckman Coulter), CD16 (3G8, Biolegend), CD19
(HIB19, BD), CD38 (LS198–4–3, Beckman Coulter), CD27 (O323, eBioscience),
IgD (IA6–2, eBioscience), HLA-DR (L243, Biolegend), Ki67 (Ki-67, Biolegend).
Cryo-EM. 2.8 µL of sample was applied on a carbon-coated Quantifoil R2/1 grid
that was freshly glow-discharged in the presence of amylamine to prevent preferred
orientations41. Furthermore, the grid was plunged into liquid ethane using a FEI
Vitroblot IV at 5 °C and 95% humidity with a blot force setting of 5, blot time of 3 s
and a wait time of 20 s. The grids were imaged with a 300 kV JEOL JEM-3200FS
microscope at a magniﬁcation of ×30,000, calibrated pixel size of 1.2 Å and an
underfocus range of 1–3 µm. The images were recorded with a Gatan K2 Summit
direct electron detector, where each image is composed of 50 individual frames
with an exposure time of 10 s and a total dose of 60 e−Å−2. A total of 2622
micrographs were collected in three sessions.
Image processing and 3D reconstruction. Images were motion corrected using
MotionCor242, followed by removal of bad micrographs by visual screening for
drift and high/low defocus. In addition, micrographs where Thon rings did not
extend beyond 10 Å were also excluded. Furthermore, particles were picked using
swarm from EMAN243 followed by manual removal of false positives and inclusion
of false negatives. CTF calculations were done with GCTF44 and particle coordi-
nates were imported to RELION 2.045, where all next steps were performed. An
initial group of 505,880 raw particles were extracted using a 256 × 256 pixel box
size and 2D classiﬁcation was performed. Particles belonging to the best classes
were selected and regrouped, yielding a total of 478,709 particles. A preliminary 3D
classiﬁcation and reﬁnement was performed using the human constitutive 20S
proteasome41 as initial model and the resulting map was then used for further
processing. Further 3D classiﬁcation followed using a 20 Å low-pass ﬁltered elec-
tron density map where initially C1 symmetry was used to remove bad classes,
yielding 378,196 particles, and C2 symmetry for further rounds. Next, 3D reﬁne-
ment was performed and a 4.65 Å map was generated as well as a solvent mask.
The process was repeated using a solvent mask for 3D classiﬁcation and 3D
reﬁnement, yielding a 4 Å map from 75,017 particles. In addition, movie reﬁne-
ment and particle polishing were performed using a running average of 15 frames.
A ﬁnal round of 3D reﬁnement using the polished particles and subsequent post
processing with correction of the modular transfer function of the detector and
negative B factor application resulted in a ﬁnal map of 3.8 Å where the Fourier shell
correlation is 0.143. Local resolution was estimated with RELION 2.045.
Structural modeling with reﬁnement and validation. As an initial model, the
crystal structure of human constitutive proteasome (PDB code 5LF1)25 was ﬁrst
docked and ﬁtted into the density map using COOT46 and Chimera47. The
structures of β1, β2 and β5 were then replaced by models of human immuno-
proteasome subunit β1i, β2i, and β5i respectively, which were generated from the
crystal structure of the mouse immunoproteasome (PDB code 3UNH)31 using the
SWISS-MODEL server48. The entire human immunoproteasome atomic model
was subsequently adjusted manually and rebuilt in COOT. Rigid body and real
space reﬁnements of the resulted atomic model were then performed by Phenix49.
We also performed the reciprocal space reﬁnement procedure with the application
of secondary structure and stereochemical constraints in the program Phenix.
Finally, the atomic model was validated using MolProbity50. Structural ﬁgures were
prepared in Chimera47 and Pymol (https://www.pymol.org). The ﬁnal model was
cross validated using a method described previously51, which indicated that our
model was not over-ﬁtted.
Cell-based proteasome β5 activity assay. Intracellular proteasomal activity and
inhibition assay were performed as reported14. Karpas 1106P (80,000 cells per well)
were plated and incubated with compound at indicated concentrations for 1 h at
37 °C. The activity of the overall β5 activity including β5i and β5c in each was
measured in situ after compound removal with Proteasome-Glo assay kit according
to manufacturer’s instructions. Luminescence was recorded on a SpectraMax M5
plate reader. Relative percentage of RLU was used to calculate the IC50s.
Malignant B-cell cytotoxicity assays. We used Karpas 1106P B lymphoma cell
line (Cat. No. 06072607, Aldrich)15,16,52, HepG2 (HB-8065, ATCC), MM.1S (Cat.
No. CRL-2974, ATCC). Cells were cultured at 37 °C in a humidiﬁed air/5% CO2
atmosphere in medium supplemented with 10% fetal bovine serum, except for the
medium for Karpas 1106P cells which contained 20% fetal bovine serum, and 100
units per ml penicillin, 100 μg per ml streptomycin in RPMI 1640 medium. Karpas
1106P was used at 80,000 cells per well, MM.1S at 100,000 cells per well, and
HepG2 at 12,000 cells per well. Cells plated in a 96-well plate were treated with
compounds at indicated concentrations for 72 h at 37 °C in a tissue culture incu-
bator with 5% CO2. Viable cells were counted using Cell-titer Glo assay kit. EC50s
were calculated using PRISM (Graphpad).
Antibody-secreting cell differentiation from human PBMC. Human peripheral
blood samples were obtained from ﬁve different healthy volunteers (BWH Speci-
men Bank). Peripheral blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation using Lymphoprep (StemCell Technologies). PBMCs were
cultured at 1.5 × 106 cells per mL in RPMI 1640 media (Lonza), supplemented with
10% human serum (GemCell) (10% HS-RPMI), recombinant human IL-2 10 ng
per mL (or 100 U per ml, BioLegend) and R848 1 µg per mL (Cayman Chemicals)
for 5 days, at 37 °C, 5% CO2. PKS21221 in DMSO, or DMSO only for control, was
added to the culture media on day 5, and cells were incubated for additional 12, 24,
and 48 h. Cells were then stained with surface marker antibodies and analyzed by
ﬂow cytometry. The viability and apoptosis were assessed using Annexin V
Apoptosis Detection Kit (BD Biosciences).
Viability assay of human PBMC. Human PBMCs were obtained from 5 different
healthy volunteers as above. Isolated PBMCs were incubated in 10% HS-RPMI at
5 × 105 cells per 200 μl per well in 96-well round bottom plate (Corning), for 12, 24,
Table 3 Inhibition of intracellular proteasomal activities and cytotoxicity of PKS21221
IC50a (nM) EC50a (nM)
Karpas β5i Karpas β5(i+c) HepG2 β5c MM.1S RPMI 8226 Karpas HepG2
172± 33 118± 33 1833± 138 78± 30 66± 6 740± 145 2320± 630
β5i activity was assayed with (Ac-ANW)2-R110
β5(i+c) and β5c activity were assayed with suc-LLVY-luciferin
β5(i+c) deﬁnes the total chymotryptic activity inside the Karpas cells
aData are means± SEM of three to four independent experiments
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48 h, in the presence of different concentrations of PKS21221 or Bortezomib
(Selleckchem). The viability of different populations of PBMCs, such as T cells
(CD3+), B cells (CD19+CD3−CD14−), monocytes (CD14+), dendritic cells (CD3
−CD19−CD14−CD16−HLADR+CD11c+), were assessed by ﬂow cytometry using
Fixable Viability dye (Themo Fisher).
In vitro T cells activation and proliferation. T cells were isolated from human
PBMCs using Human T-cell Isolation kit (StemCell Technologies, Cat#17951). The
purity of T cells was greater than 90% as conﬁrmed by ﬂow cytometry. Cells were
counted and loaded with 5 μM CellTrace Violet (Thermo Fisher) in phosphate
buffered saline (PBS) for 10 min at 37 °C, followed by wash in 10% fetal calf serum
(FCS)-supplemented RPMI 1640 media. T cells were cultured in 10% HS-RPMI,
with anti-CD3 (1 μg per mL, eBioscience) and anti-CD28 (1 μg per mL,
eBioscience), in the presence or absence of different concentration of PKS21221 or
Bortezomib (Selleckchem). In some experiments, T cells were cultured in 10% HS-
RPMI / anti-CD3 / anti-CD28 for 4 days and then treated with PKS21221 or
Bortezomib (Selleckchem) for 12, 24, 48 h. The viability and apoptosis were
assessed using Annexin V Apoptosis Detection Kit (BD Biosciences). The experi-
ments were performed in cells from three different healthy volunteer donors.
Flow cytometry. Cells were stained with surface marker antibodies at pre-titrated
concentrations, in 2% FCS-containing PBS on ice for 30 min. For intracellular
staining of Ki67, surface-stained cells were washed with 2% FCS-PBS, followed by
incubation in ﬁxation/permeabilization buffer (eBioscience) on ice for 45 min and
intracellular staining in permeabilization buffer (eBioscience) for 30 min at room
temperature. Cells were analyzed using FACS CantoII (BD Biosciences) and BD
FACS Diva software (BD Bioscience). Data were analyzed by FlowJo software
(version 10, Tree Star). Gating strategies for each experiment were provided in the
supplementary information.
Data availability. All the relevant data are available within the paper and its
Supplementary Information ﬁle or from the corresponding authors upon reason-
able request. The cryo-EM 3D map has been deposited in the EMDB database with
accession code EMD-7010. The corresponding atomic model has been deposited in
the RCSB PDB with accession code 6AVO.
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